Overview

Pharmacokinetics Study of ALO-02 and OxyContin

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

To characterize the single- and multiple-dose pharmacokinetics of oxycodone following the administration of ALO-02 40 Mg Twice Daily, ALO-02 80 Mg Once Daily or Oxycontin 40 Mg Twice Daily in Healthy Volunteers

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Naltrexone
Oxycodone